The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Omicron Antigens Now Available

New RBD antigens now available for SARS-CoV-2 Omicron BA.5 variant. The Native Antigen Company also offers whole Spike, S1 and RBD antigens for the SARS-CoV-2 Omicron (B.1.1.529) variant.

Produced from our VirtuE expression system, our Spike antigens exhibit full glycosylation and proper folding, ideal for developing high quality immunoassays and raising highly specific antibodies.

About the Omicron Variant

The B.1.1.529 SARS-CoV-2 variant was designated Omicron on 26th November 2021, following its increasing prevalence in South Africa, harbouring more than 30 mutations in its Spike gene. BA.2 was designated a Variant of Concern (VOC) due to principal concerns surround Omicron’s infectivity, virulence and ability to circumvent vaccine protection (WHO Classification of Omicron Nov 2021).

More recently, additional mutations in the BA.2 variant, variants BA.4 and BA.5, appear to have given transmissional advantages (Mahase 2022). BA.4 and BA.5 were first detected in South Africa in January and February 2022, respectively, where BA. 5 now accounts for more than half of the world’s cases, while BA. 4 just over one in ten (WHO Cronovirus Dashborad).

The World Health Organisation (WHO), in consultation with the Technical Group on Virus Evolution, have designated BA. 4 and BA. 5 as variants of concern (VOC) (Tracking SARS-CoV-2 Variants, WHO). The spike mutations of interest have been summarised in the table below (adapted from ECDC SARS-CoV-2 VOC Oct 2022).

WHO Designation Lineage Spike mutations of interest (Spike mutation being monitored*) Month & Year first detected
Omicron BA. 2 G142D, N211I, Δ212, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K November 2021
Omicron BA. 4 L452R, F486V, R493Q, R346X* January 2022
Omicron BA. 5 L452R, F486V, R493Q, R346X* February 2022

Our Antigens

The Native Antigen Company now offers four Spike antigens for the SARS-CoV-2 Omicron variant:
Whole Spike Antigen (REC32008)

Our trimeric whole Spike antigen is stabilised as a pre-fusion trimer via six amino acid (HexaPro) changes in the S2 subunit, in addition to a GSAS mutation in the furin cleavage site and a His-Strep-tag at the C-terminus for ease of purification.

 

Spike S1 Antigen (REC32006)

Our Spike S1 antigen includes residues 1-674 of the full Spike sequence and a C-terminal sheep Fc-tag for ease of purification.

Spike RBD Antigen

Our Spike receptor-binding domain (RBD) antigen includes residues 319-542 of the full Spike sequence and a C-terminal His-tag for ease of purification.

SARS-CoV-2 Omicron BA.5 Antigen

Our Spike receptor-binding domain (RBD) antigen includes residues 23-245 (NCBI URX31554.1) of the full Spike sequence and a C-terminal His-tag for ease of purification.

Our antigens are available in 100μg and 500μg sizes, as well as bulk supply of multiple grams.

Produced from our VirtuE expression system, our Spike antigens exhibit full glycosylation and proper folding, ideal for developing high quality immunoassays and raising highly specific antibodies.

For more information on these products, get in touch with a member of our team.

Red Spike Trimer, White Glycans
Antigen Mutations in Reference to Wuha-Hu-1 Wild-Type

 

 

Whole Spike
(REC32008)

A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N
N440K,
G446S, S477N, T478K, E484A, Q493R, G496S, Q498RN501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F
Spike S1
(REC32006)
A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y
Spike RBD
(REC32007)
G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H
Spike BA.5
(REC32036)
G339D, S371F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H

Get in touch

Would you like to be kept informed of the latest news and innovations from the infectious disease community? Please let us know if you would like us to contact you or not by selecting one of the options below.

15 + 2 =

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

New antigens support research into BA.5 variant, currently responsible for over half of global COVID-19 cases Oxford, UK, 02 November 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables...

The Role of Serology in Tracking COVID-19 Mutations

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...

Preparing for Disease Y: A Better Serological Toolbox

This article was originally published on Clinical Lab Manager. It’s been over a year since the World Health Organization (WHO) declared COVID-19 a pandemic. SARS-CoV-2 has since infected 200 million people, resulting in nearly 4 million deaths and substantial economic...

Keeping Up with the New SARS-CoV-2 Variant Nomenclature

If you’ve been struggling to make sense of SARS-CoV-2 variant nomenclature, you’re not alone. Due to the existence of multiple genomic sequence databases, various naming systems are in use for the rapidly growing range of SARS-CoV-2 variants of concern/interest. In a...

Making Sense of the SARS-CoV-2 Spike Mutations

Through much of 2020, SARS-CoV-2 accumulated mutations at a steady, yet unspectacular rate. However, as global cases approached 100 million by the end of the year, multiple variants began to emerge. Exhibiting more considerable genomic changes, some variants have...

D614G: Putting the Mutation in Perspective

Since the emergence of SARS-CoV-2, scientists have speculated about the risks of mutation and what this could mean for therapeutics and vaccines. In this blog, we explore the nature viral mutation, what is known about the D614G mutant of SARS-CoV-2, and introduce our...

The Endemic Coronaviruses and What They Might Tell us About COVID-19

While less-well known than some of their counterparts, the 229E, NL63, OC43, and HKU1 human coronaviruses are a significant cause of respiratory disease worldwide. The evolutionary histories and host associations of the endemic coronaviruses also provide important...

Q&A: An Insight Into COVID-19 Serology

During the course of the current coronavirus pandemic, we have all been aware of the urgent need for nucleic acid testing to identify people currently infected with SARS-CoV-2. The second form of testing needed are serological immunoassays, which can identify past...

A Q&A with David Flavell of Leukaemia Busters

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in the...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

Designing for Differentiation: Why We Need Highly Specific Diagnostics for a COVID-19 Vaccine

Assessment of vaccine-induced immune responses in clinical trials will require highly specific diagnostic assays to ensure safety. This blog was originally published on Clinical Lab Manager.The Vaccine Race Vaccines are the most effective means of preventing...

An Early Look at Vaccines for COVID-19

In the first of a three-part series on the design, immunology and manufacture of COVID-19 vaccines, we take an early look at the major technologies under development and weigh-up the challenges these vaccines will face in reaching late-phase clinical trials.Why We...

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

Coronaviruses: The Next Disease X?

For much of their known history, the coronaviruses were regarded as relatively benign pathogens with little potential to cause human harm. However, the emergence of SARS and MERS in recent decades has brought coronaviruses into the global spotlight. In this blog we...